ZNTL
Zentalis Pharmaceuticals Llc
NASDAQ: ZNTL · HEALTHCARE · BIOTECHNOLOGY
$4.01
+1.26% today
Updated 2026-04-30
Market cap
$287.27M
P/E ratio
—
P/S ratio
7.13x
EPS (TTM)
$-1.91
Dividend yield
—
52W range
$1 – $7
Volume
2.2M
WallStSmart proprietary scores
30
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.5
Quality
B3.0
Profitability
D4.0
Valuation
C2/9
Piotroski F-Score
Weak
-1.5
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$6.25
+55.86%
12-Month target
—
—
Intrinsic (DCF)
$1.62
Margin of safety
-50.00%
0 Strong Buy4 Buy5 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Debt/equity 0.15x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -1.45 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-30.94M
- 50.00% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $67.42M | $0.00 | $26.86M |
| Net income | $-236.81M | $-292.19M | $-165.84M | $-137.06M | $-35.22M |
| EPS | — | — | — | — | $-1.91 |
| Free cash flow | $-166.30M | $-208.41M | $-171.08M | $-125.25M | $-30.94M |
| Profit margin | — | — | -245.96% | — | — |
Peer comparison
Smart narrative
Zentalis Pharmaceuticals Llc trades at $4.01. Our Smart Value Score of 30/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -1.45, it sits in the distress. TTM revenue stands at $26.86M. Our DCF model estimates intrinsic value at $1.62.
Frequently asked questions
What is Zentalis Pharmaceuticals Llc's stock price?
Zentalis Pharmaceuticals Llc (ZNTL) trades at $4.01.
Is Zentalis Pharmaceuticals Llc overvalued?
Smart Value Score 30/100 (Grade F, Strong Sell). DCF value $1.62.
What is the price target of Zentalis Pharmaceuticals Llc (ZNTL)?
The analyst target price is $6.25, representing +55.9% upside from the current price of $4.01.
What is the intrinsic value of Zentalis Pharmaceuticals Llc (ZNTL)?
Based on our DCF model, intrinsic value is $1.62, a -50.0% margin of safety versus $4.01.
What is Zentalis Pharmaceuticals Llc's revenue?
TTM revenue is $26.86M.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
-1.45 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio7.13x
ROE-49.50%
Beta1.66
50D MA$3.12
200D MA$2.07
Shares out0.07B
Float0.05B
Short ratio—
Avg volume2.2M
Performance
1 week-18.91%
1 month+113.12%
3 months+81.08%
YTD+297.04%
1 year—
3 years—
5 years—